Rybelsus tablets 7 mg for type II diabetes mellitus (semaglutide)

What are Rybelsus tablets 7 mg for type II diabetes mellitus? 

Rybelsus tablets, designed by Novo Nordisk for the management of type 2 diabetes mellitus, incorporate the active ingredient known as semaglutide. Semaglutide is classified as a GLP-1 receptor agonist, exerting its pharmacological action by modulating blood glucose levels within the body. Rybelsus tablets operate through mechanisms that entail the stimulation of insulin release and the suppression of glucagon secretion, ultimately culminating in reduced blood glucose levels. Clinical investigations have demonstrated noteworthy reductions in HbA1c levels when Rybelsus tablets are administered, signifying improved long-term blood sugar control. Furthermore, it is noteworthy that some individuals may experience weight loss as an ancillary benefit when utilizing these tablets, which can be particularly advantageous for those managing type 2 diabetes. Research findings have also indicated that semaglutide administration yields a notable 26% reduction in the risk of major adverse cardiovascular events, inclusive of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke.

Active principles: semaglutide (genetical recombination)

Amount: 100 tablets 

Maker: Novo Nordisk Pharma Ltd., Tokyo, Japan

Indications: treatment of type II diabetes mellitus

How to take

Adults should start with a daily dosage of 3 mg of active principle a day, and after taking it for 4 weeks or more increase up to the maintenance dose of 7 mg once a day. If the effect is insufficient even after taking 7 mg once a day for 4 weeks or more, the dose may be increased to 14 mg once a day. You doctor can adjust the dosage at any time according to your symptoms. 

Please note that this medicine contains 7 mg of the active principle in 1 tablet. 

This medicine should be taken on an empty stomach before the first meal or drink of water of the day.

Take 1 tablet with about half a glass of water (approximately 120 ml or less). 

Avoid eating, drinking, and taking other medications for at least 30 minutes after taking this medication.

Do not divide, crush, or chew this medicine before taking it.

Contraindications: do not use for the following patients:

• patients with a gastrointestinal disorder such as gastroparesis,
• patients with type 1 diabetes,
• patients with a history of pancreatitis,
• patients who have had stomach removal surgery,
• pregnant, possibly pregnant, planning to become pregnant within the next 2 months, or breastfeeding women. 

Important information

This medicine is highly hygroscopic, so please remove it from the PTP sheet immediately before taking it. Do not touch it with the wet hands. Since the PTP packaging sheet is moisture-proof, do not cut it off at any point other than the perforations.

Patient should strictly follow the prescribed diet and exercise regimen.

As hypoglycemia symptoms may occur, patient should pay close attention when operating dangerous machinery, working at heights or driving a car. In case symptoms of hypoglycemia occur, patient should immediately take sugar. If patient is taking this medicine at the same time as an alpha-glucosidase inhibitor, they should take glucose in case of any hypoglycemia symptoms.

In rare cases of persistent severe abdominal pain accompanied by vomiting, patient should stop taking this medicine and promptly consult with their doctor to avoid the occurrence of acute pancreatitis.

In case of thyroid-related symptoms (such as a hard lump on your neck), patient should consult with their doctor and see a specialist if needed.

If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.